Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - dicamba as the sodium salt - water soluble granules - dicamba as the sodium salt benzoic acid-arylaliphatic active 700.0 g/kg - herbicide - barley - see label | between cropping | commercial rye - see label | conservation tillage weed control | direct drill | fallow ( - afghan thistle | amaranth or amaranthus | amsinckia,yellow burrweed or burr grass | angled onion | annual gooseberry | annual or wimmera ryegrass | apple-of-peru | artichoke thistle | barnyard grass or water grass | bathurst burr | bellvine | billygoat weed or blue top | bindy-eye | blackberry nightshade | bladder campion | bladder ketmia | broadleaf dock | calopo | caltrop or yellow vine | canary grass | capeweed | capeweed - suppression | cat's ear or flatweed | centro | charlock | chickweed | cleome | climbing buckwheat | clover | cobbler's pegs | common cotula or carrot weed | common iceplant | common pigweed | common sensitive plant | common vetch or tares | convolvulus genus | cotton thistle | creeping knotweed | creeping oxalis | cudweed | dandelion - taraxacum officinale | datura spp. | deadnettle | dock | dock - seedling | dwarf amaranth or boggabri weed | fat hen | field bindweed | fleabane | fumitory | giant or black pigweed | green amaranth | ground or annual ground cherry | hedge or wild mustard

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - dicamba as the sodium salt - water dispersible granule - dicamba as the sodium salt benzoic acid-arylaliphatic active 700.0 g/kg - herbicide - agricultural non-crop areas | barley | commercial rye | conservation tillage weed control | direct drill | fallow (no tillage) | - afghan thistle | amaranth or amaranthus | amsinckia,yellow burrweed or burr grass | annual gooseberry | annual ground cherry | annual ryegrass | apple-of-peru | artichoke thistle | barnyard grass or water grass | bathurst burr | bellvine | billygoat weed or blue top | bindy-eye | blackberry nightshade | bladder campion | bladder ketmia | broadleaf dock | calopo | caltrop - tribulis terrestis | caltrop or yellow vine | canary grass | capeweed | cat's ear or flatweed | centro | charlock | chickweed | cleome | climbing buckwheat | clover | cobbler's pegs | common iceplant | common sensitive plant | common vetch or tares | convolvulus genus | cotton thistle | cotulas | creeping knotweed | creeping oxalis | cudweed | curled dock | dandelion - hypochaeris glabra | datura spp. | deadnettle | dock | dock - seedling | dwarf amaranth or boggabri weed | fat hen | field bindweed | fleabane | fumitory | giant or black pigweed | green amaranth | hoary cress or whiteweed | horehound | iceplant | illyrian thistle | indian he

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - dicamba as the sodium salt - water dispersible granule - dicamba as the sodium salt benzoic acid-arylaliphatic active 700.0 g/kg - herbicide

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, neona

United States - English - NLM (National Library of Medicine)

sigmapharm laboratories, llc - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of t

United States - English - NLM (National Library of Medicine)

kvk-tech, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)]. sodium polystyrene sulfonate is contraindicated in patients with the following conditions: • hypersensitivity to polystyrene sulfonate resins • obstructive bowel disease • neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1 meq potassium per 1 gram of resin. in neonates, sodium polystyrene sulfonate should not be given by the oral route. in both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate use [see warnings and precautions (5.4)] .

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 500 mg - sodium phenylbutyrate tablets is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, ne

United States - English - NLM (National Library of Medicine)

puracap laboratories, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 4.1 meq in 1 g - sodium polystyrene sulfonate powder, for suspension is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate powder, for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate powder, for suspension is contraindicated in patients with the following conditions: ● hypersensitivity to polystyrene sulfonate resins ● obstructive bowel disease ● neonates with reduced gut motility risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients,